Quick summary
Humanin is a 24-amino acid mitochondrial-derived peptide that declines with age. It protects neurons from amyloid-beta toxicity, improves insulin sensitivity, and extends healthspan in animal models, representing a novel class of mitochondria-encoded signaling peptides.
Overview
Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. First identified in 2001 from brain tissue of an Alzheimer's patient, humanin is an endogenous cytoprotective factor that declines with age. It protects neurons from amyloid-beta toxicity, improves insulin sensitivity, reduces systemic inflammation, and extends healthspan in multiple animal models. Humanin represents a novel class of mitochondria-encoded signaling peptides with broad implications for aging and neurodegeneration.
Mechanism of action
Humanin acts through two main receptor systems. Extracellularly, it signals via a heterotrimeric receptor complex comprising ciliary neurotrophic factor receptor alpha (CNTFRα), WSX-1, and gp130, activating JAK2/STAT3 and PI3K/Akt pro-survival pathways. Intracellularly, humanin directly binds and inhibits pro-apoptotic Bax protein, preventing mitochondrial outer membrane permeabilization and cytochrome c release. In neuronal contexts, humanin blocks amyloid-beta (Aβ) oligomer-induced apoptosis by inhibiting Aβ binding to cell surface receptors and downstream caspase activation. It also suppresses inflammatory NF-κB signaling, improves mitochondrial membrane potential, and enhances autophagy to clear damaged organelles. Humanin levels in plasma and CSF correlate inversely with Alzheimer's disease severity.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Neuroprotection / metabolic healthspan (preclinical protocol) | subcutaneous | 2.5–5 mg/kg | twice weekly | Mouse study protocols only. No validated human dosing exists. Community use is entirely extrapolated from animal data. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Animal studies demonstrate that humanin and its potent synthetic analogue HNG (S14G-Humanin) extend lifespan in C. elegans, improve cognitive function in aged mice, protect against diet-induced obesity and insulin resistance, and reduce amyloid plaque burden in AD models. Human studies show CSF humanin levels are significantly reduced in Alzheimer's disease patients versus controls. Epidemiological data links higher plasma humanin to better cognitive aging outcomes. A Nature Scientific Reports study found twice-weekly HNG administration improved metabolic healthspan markers and reduced inflammatory markers in middle-aged mice. No human clinical trials of exogenous humanin have been completed as of 2026.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Humanin for synergistic effects.
Legal status
Research chemical only. No FDA-approved humanin therapeutic exists. Available from peptide research suppliers. No human clinical trials completed or registered as of 2026.
Sourcing & access
Research compound
Humanin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Humanin is a 24-amino acid peptide encoded within the 16S ribosomal RNA gene of the mitochondrial genome. First identified in 2001 from brain tissue of an Alzheimer's patient, it is an endogenous cytoprotective factor that declines with age and has broad implications for aging and neurodegeneration.
Humanin signals extracellularly via a CNTFRalpha/WSX-1/gp130 receptor complex, activating JAK2/STAT3 and PI3K/Akt survival pathways. Intracellularly, it directly binds and inhibits pro-apoptotic Bax protein. It blocks amyloid-beta-induced apoptosis and suppresses NF-kB inflammatory signaling.
No human safety data exists since no human clinical trials have been completed. Theoretical risks include hypoglycemia from insulin-sensitizing effects. Known side effects from research contexts are limited to injection site reactions.
CSF humanin levels are significantly reduced in Alzheimer's patients versus controls, and higher plasma humanin correlates with better cognitive aging outcomes. Animal studies show the synthetic analog HNG reduces amyloid plaque burden and improves cognitive function in AD models.
Research references
- The mitochondrial derived peptide humanin is a regulator of lifespan and healthspanPubMed
- Humanin and Its Pathophysiological Roles in Aging: A Systematic ReviewReview
- Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognitionPubMed
- Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and PerspectivesPubMed
- Cardio-protective role of Humanin in myocardial ischemia-reperfusionPubMed